Transthera Sciences won NMPA approval in China for Yochanra (tinengotinib) in FGFR2-positive cholangiocarcinoma that progressed after FGFR inhibitor therapy. The designation targets a post–targeted-therapy setting where patients often have limited next-line options. The approval reflects continuing momentum for precision oncology in China, where biomarker-defined indications are increasingly moving to registration after targeted-exposure failure. It also sets up a new competitive segment in the sequence of care for FGFR-driven biliary cancers. Clinically, the update matters most for patients who have already received FGFR inhibitor regimens and need an orally administered alternative that remains aligned to the pathway biology.